Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices

ConclusionsOral milrinone appears safe for long-term use in the outpatient setting when combined with therapeutic monitoring in this complex medical cohort with limited management options. Further study is needed to ascertain whether this treatment is effective in reducing heart failure symptoms and admissions.

Source: ESC Heart Failure - July 30, 2022 Category: Cardiology Authors: Waqas Akhtar, Charles Butcher, Andrew Morley ‐Smith, Fernando Riesgo Gil, Owais Dar, Veronica Baston, John Dunning, Haifa Lyster Tags: Short Communication Source Type: research